Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 5/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 4/20 | 0.66 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.66 |
| ▸ | KCNK2 | O95069 | 2/20 | 0.66 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.66 |
| ▸ | CACNA1C | Q13936 | 2/20 | 0.66 |
| ▸ | SLC7A5 | Q01650 | 4/20 | 0.61 |
| ▸ | MEN1 | O00255 | 4/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.61 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.61 |
| ▸ | NPC1 | O15118 | 2/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | MTOR | P42345 | 2/20 | 0.61 |
| ▸ | RAB9A | P51151 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | TP53 | P04637 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13050366 | 1.00 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL13050367 | 1.00 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| Hydrochloric Acid SCHEMBL4777538 | 0.99 | SLC6A4 (0.64) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL8025883 | 0.86 | SLC6A4 (0.63) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7049659 | 0.85 | SLC6A4 (0.53) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL2738930 | 0.82 | SLC6A4 (0.78) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL5533205 | 0.82 | SLC6A9 (0.46) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL10439502 | 0.82 | SLC6A4 (0.61) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL7306077 | 0.80 | SLC6A4 (0.59) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 | |
| SCHEMBL3746826 | 0.80 | SLC6A4 (0.66) | SLC6A4SLC6A2SLC6A3KCNK2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154378-A1 | SUBSTANCE USE DISORDER PREVENTION OR TREATMENT WITH LOW INTENSITY AND HIGH FREQUENCY MAGNETIC STIMULATION | ACTIPULSE NEUROSCIENCE INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-1434763-B1 | BETA-LACTAMYL VASOPRESSIN V1A ANTAGONISTS | AZEVAN PHARMACEUTICALS INC (US) | 2018-01-17 | — | — | EP | disclosed |
| EP-2755644-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR | Novartis AG (CH) | 2014-07-23 | — | — | EP | disclosed |
| WO-2013037713-A1 | COMBINATIONS COMPRISING A S1P RECEPTOR MODULATOR | NOVARTIS AG (CH) | 2013-03-21 | — | — | WO | disclosed |
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AZEVAN PHARMACEUTICALS, INC. (US) | 2008-05-15 | — | — | US | disclosed |
| WO-2008052086-A1 | BENZODIOXANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| WO-2008052087-A1 | CHROMANE DERIVATIVES AND USES THEREOF | WYETH (US) | 2008-05-02 | — | — | WO | disclosed |
| EP-1871755-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | Wyeth (US) | 2008-01-02 | — | — | EP | disclosed |
| WO-2006116150-A1 | DIHYDROBENZOFURAN DERIVATIVES AND USES THEREOF | WYETH (US) | 2006-11-02 | — | — | WO | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| EP-1397145-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | Müller, Norbert (DE) | 2004-03-17 | — | — | EP | disclosed |
| WO-2002102297-A2 | USE OF COX-2 INHIBITORS FOR THE TREATMENT OF SCHIZOPHRENIA, DELUSIONAL DISORDERS, AFFECTIVE DISORDERS, AUTISM OR TIC DISORDERS | MUELLER NORBERT (DE) | 2002-12-27 | — | — | WO | disclosed |
| EP-0998467-A1 | PREPARATION AND USE OF 2-METHYL-5-PHENYLISOXAZOLIDINE | ALBEMARLE CORPORATION (US) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999005129-A1 | PREPARATION AND USE OF 2-METHYL-5-PHENYLISOXAZOLIDINE | ALBEMARLE CORPORATION (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0343830-A2 | Ring-substituted 2-amino-1,2,3,4-tetrahydronaphthalenes | ELI LILLY AND COMPANY (US) | 1989-11-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113959-A1 | {Beta}-Lactamyl vasopression V1a antagonists and methods of use | AVPR1A, AVPR2, AVPR1B | SLC6A4 555/4885SLC6A2 293/4885SLC6A3 442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.